The Radioligand Therapy Readiness Assessment Framework and accompanying user guide were developed in collaboration with an International Expert Advisory Group. The multidisciplinary group had full editorial control over content of these materials, which reflect group consensus. All members provided their time for free.

We would like to thank group members for their contribution:

Natcha Bolanos

Global Alliances Manager, Lymphoma Coalition, Spain

Dr Erik Briers

Patient Advocate, Europa Uomo; patient representative and member of Guidelines Committee on the treatment of prostate cancer, European Association of Urology, Belgium

Dr John Buscombe

Locum Consultant Physician in Nuclear Medicine, Barts Health NHS Trust, UK

Professor Martin Dreyling

Senior Physician, LMU Klinikum, Germany

Dr Ajay Gopal

Professor of Medicine, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Alliance US

Dr Boris Hadaschik

Head of Department and Full Professor, Department of Urology, Essen University Hospital, Germany

Professor Ken Herrmann

Chair, Department of Nuclear Medicine, Essen University Hospital, Germany

Nikie Jervis

Senior Patient Support, Information Nurse Specialist and Education Lead, Neuroendocrine Cancer UK; International Neuroendocrine Cancer Alliance, UK

Dr Jolanta Kunikowska

Associate Professor, Nuclear Medicine and Internal Medicine Physician, Nuclear Medicine Department, Medical University of Warsaw; European Association of Nuclear Medicine, Poland

Josh Mailman

President, Northern California CarciNET Community, US

Professor Nicolas Mottet

Professor of Urology, University Jean Monnet, France

Professor Jens Siveke

Director, Bridge Institute of Experimental Tumor Therapy, German Cancer Consortium, Germany

Professor Hein Van Poppel

Adjunct Secretary General for Education, European Association of Urology; University Hospital Gasthuisberg; Professor of Urology, Katholieke Universiteit Leuven (KU Leuven), Belgium

Lorna Warwick

Chief Executive Officer, Lymphoma Coalition, Canada

Get in touch

For more information about this project, contact us at

We’re on Twitter! Follow @radioligand¬†for updates on this project and other exciting developments in targeted cancer care.